Who owns Monte Rosa Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of GLUE from SEC Form 13F filings across 192 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 192 institutions disclosed 92.7M shares of Monte Rosa Therapeutics, Inc. worth $2.24B — about 91.3% of shares outstanding; the largest disclosed holder is PRICE T ROWE ASSOCIATES INC /MD/. Source: SEC Form 13F filings, parsed by EvidInvest.
192
13F holders
$2.24B
value, 2026 filers
91.3%
of shares outstanding (92.7M sh)
29
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of GLUE's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | PRICE T ROWE ASSOCIATES INC /MD/ | 8.9M | $214.4M | 0.0% | 8.7% | +31.9% |
| 2 | NEA Management Company, LLC | 7.7M | $186.2M | 11.7% | 7.6% | 0.0% |
| 3 | BlackRock, Inc. | 6.8M | $165.6M | 0.0% | 6.7% | +21.4% |
| 4 | TCG Crossover Management, LLC | 4.6M | $111.9M | 2.7% | 4.6% | 0.0% |
| 5 | Vestal Point Capital, LP | 4.6M | $111.3M | 2.6% | 4.5% | +27.7% |
| 6 | BVF INC/IL | 4.5M | $108.0M | 2.8% | 4.4% | 0.0% |
| 7 | BAKER BROS. ADVISORS LP | 4.3M | $105.2M | 0.5% | 4.3% | 0.0% |
| 8 | STATE STREET CORP | 3.7M | $90.3M | 0.0% | 3.7% | +11.3% |
| 9 | MONTANOVA CAPITAL, LLC | 3.5M | $85.9M | 1.6% | 3.5% | -16.0% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 3.4M | $82.6M | 0.0% | 3.4% | +10.1% |
| 11 | Versant Venture Management, LLC | 3.2M | $77.0M | 47.3% | 3.1% | 0.0% |
| 12 | BRAIDWELL LP | 2.5M | $59.3M | 2.2% | 2.4% | -23.5% |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1.9M | $45.1M | 0.0% | 1.8% | +21.0% |
| 14 | AMERICAN CENTURY COMPANIES INC | 1.6M | $39.3M | 0.0% | 1.6% | -42.2% |
| 15 | MARSHALL WACE, LLP | 1.6M | $38.6M | 0.0% | 1.6% | +11.2% |
| 16 | Aisling Capital Management LP | 1.6M | $37.6M | 8.0% | 1.5% | 0.0% |
| 17 | Bellevue Group AG | 1.2M | $28.8M | 0.6% | 1.2% | -4.8% |
| 18 | DIMENSIONAL FUND ADVISORS LP | 1.2M | $28.5M | 0.0% | 1.2% | +13.1% |
| 19 | MPM BIOIMPACT LLC | 1.2M | $28.1M | 1.7% | 1.1% | -1.3% |
| 20 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.1M | $26.8M | 2.8% | 1.1% | -44.6% |
| 21 | Jupiter Topco LLCNEW | 1.1M | $26.0M | 0.0% | 1.1% | new |
| 22 | Frazier Life Sciences Management, L.P. | 1.0M | $24.2M | 0.5% | 1% | 0.0% |
| 23 | GOLDMAN SACHS GROUP INC | 998,253 | $24.2M | 0.0% | 1% | -0.3% |
| 24 | Woodline Partners LP | 962,884 | $23.3M | 0.1% | 0.9% | +1192.5% |
| 25 | FMR LLC | 934,414 | $22.6M | 0.0% | 0.9% | -8.8% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.